Introduction
The heart responds to stress or injury by hypertrophic growth, an initially compensatory structural remodelling, which often progresses to cardiac wall thinning, chamber dilation, and heart failure. Although this transition from cardiac hypertrophy to heart failure has been associated with lengthening of individual cardiomyocytes and loss of sarcomeres, MEF2 has initially been postulated to play a role in the development of cardiac hypertrophy, as its activity is upregulated by several prohypertrophic signalling cascades, including calcineurin, calcium/ calmodulin-dependent protein kinase, and mitogen-activated protein kinase pathways. 10 We and others, however, have demonstrated that overexpression of either MEF2A, MEF2C or MEF2D in the post-natal heart minimally triggers the classical hypertrophic growth response, but rather induces dilated cardiomyopathy. 4, 5, 11 At the cellular level, MEF2
activation resulted in elongation of cardiomyocytes and possibly disorganization of sarcomere structure. 4, 5 Conversely, in vivo inhibition of MEF2 activity did not prevent calcineurin-induced cardiac hypertrophy, but profoundly reduced cardiac dilation and improved contractility. 4 Furthermore, cardiac specific deletion of MEF2D protected against pressure overload-induced cardiac remodelling and dysfunction. 11 Overall, these results imply that MEF2 activates a gene program triggering cardiac dilation and loss of contractility. However, the therapeutic value of targeting MEF2 to prevent cardiac dilation and dysfunction in heart failure has been challenged, since inhibition of all MEF2 activity leads to mitochondrial dysfunction accelerating heart failure development. 12 Since previous results indicate that MEF2 regulates expression of genes controlling both the adaptive response of the heart to stress as well as genes involved in the maladaptive structural remodelling during heart failure development, we aimed to identify MEF2 target genes responsible for the adverse cardiomyocyte remodelling associated with cardiomyopathy. Here, we describe myotonic dystrophy protein kinase (DMPK) as transcriptional target of MEF2 involved in loss of sarcomere structure in heart failure.
Methods
Detailed experimental protocols are in the Supplementary Material online.
Recombinant viruses
Recombinant adenoviruses were generated as described previously. 4 Lentiviruses were generated by cloning cDNA inserts into pLenti-C-GFP (Origine, PS100065) or pLenti-C-tRFP (Origine, PS100074) and cotransfection with third-generation lentiviral packaging plasmids pMDLg/ pRRE (Addgene, 12251), pRSV-Rev (Addgene, 12253), and the pMD2.G envelope plasmid (Addgene, 12259) into HEK293T cells.
Cell culture and transient transfection assays
Neonatal rat ventricular cardiomyocytes (NRCM) were isolated from 1-3 days old Wistar rats and cultured as described before. 4 Low passage HEK293T cells were cultured in DMEM supplemented with 10% FBS. NkL-TAg cells were cultured as described previously. 13 NkL-TAg cells were transiently transfected using FuGENE 6 reagent (Roche). NRCM were transfected using Lipofectamin 2000 (Invitrogen).
Generation of stable cardiac cell lines
Two independent double stable NkL-TAg cell lines (TR1-194 and TR4-39), inducibly expressing the constitutively active MEF2VP16 (caMEF2), were generated using the T-REX system (Invitrogen).
Gene expression profiling
TR1-194 and TR4-39 clones were maintained in parallel cultures, mortalized by overnight AdCre infection, cultured for an additional 3 days in serum-free media either in the presence or absence of 24 h doxycyclin (Dox)-treatment. Three corresponding cultures were pooled, total RNA extracted using TRIzol (Invitrogen), and cleaned with Qiagen RNeasy Mini Kits (Qiagen). RNA quantity was measured with a NanoDrop V R ND-1000 UV-Vis Spectrophotometer (Wilmington), and RNA quality was monitored using an Agilent 2100 bioanalyzer. Gene expression profiling was performed using Agilent 44k mouse whole genome microarray slides following the manufacturer's protocol.
Immunofluorescence and confocal microscopy
Cultured cardiomyocytes were fixed for 10 min in 4% paraformaldehyde and permeabilized with 0.2% Triton X-100 in PBS for 5 min. Primary and secondary anti-bodies were diluted using 1% BSA in TBS and incubations were carried out at room temperature for 1 h. Cells were washed 3 times with PBS for 5 min, mounted with coverslips in 0.1 M Tris-HCl (pH 9.5)-glycerol (3 : 7) including 50 mg/mL n-propylgallate as anti-fading reagent, and analysed by confocal microscopy using a Zeiss LSM 510 META instrument or a Leica TCS SP8 X/DMI6000 inverted confocal microscope.
Histology
Hearts were fixed in 4% paraformaldehyde, dehydrated in graded alcohol solutions, and Histo-Clear and embedded in paraffin. Sections were stained with haematoxylin and eosin (H&E), or picrosirius red to determine the amount of fibrosis. For immunofluorescence, primary anti-bodies against a-actinin (A7811, Sigma, 1 : 500) and SRF (sc-335, Santa Cruz, 1 : 250) were used.
Electron microscopy
Left ventricular tissue was prefixed in 1% glutaraldehyde, 4% paraformaldehyde in 0.1 M sodium cacodylate (Merck) and processed for electron microscopy. Images were acquired with a FEI technai 12 transmission electron microscope.
Western blot analysis
Protein lysates from cells or cardiac tissue were separated by electrophoresis, transferred to polyvinylidene difluoride membranes, and processed for chemiluminescent detection. Chemiluminescence was captured by the ImageQuant LAS-4000.
Reverse-transcription and real-time polymerase chain reaction
Total RNA was isolated from the indicated cell types or tissue using TRIzol reagent (Invitrogen). One lg of RNA isolated from flash-frozen apex was reverse-transcribed using Oligo(dT) primers and Superscript II reverse transcriptase (Invitrogen). PCR amplification was performed in a total reaction volume of 50 lL and PCR products were resolved by agarose gel electrophoresis. Real-time PCR was performed in 384-well plates using SYBR Green I master solution (Roche) and the LightCycler 480 (Roche).
Chromatin immunoprecipitation
Chromatin immunoprecipitation was carried out using the Upstate Biotechnology ChIP assay kit.
Animal studies
Cardiac specific DMPK E and DMPK E (K100A) overexpression mice were generated by sub-cloning DMPK E and DMPK E (K100A) cDNA into an aMHC transgenic vector. The transgenic vectors were injected into the pronuclei of fertilized FVB oocytes, which were transferred to pseudopregnant recipients. Transverse Aortic Constriction (TAC) and echocardiography were performed as described previously. 12 For echocardiography measurement, mice were anesthetized using 1 
Statistics
The results are presented as means ± SEM. Statistical analyses were performed using INSTAT 3.0 and GraphPad Prism7 software (GraphPad, San Diego) and an unpaired 2-tailed Student's t-test, or one way ANOVA followed by Tukey's post-test. Statistical significance was accepted at a P value < 0.05.
Results

Activation of MEF2 leads to elongation and loss of sarcomeres in cultured cardiomyocytes
To address the role of MEF2 in structural remodelling of cardiomyocytes, we generated adenoviruses expressing either MEF2A (AdMEF2A) or the constitutively active MEF2VP16 (AdcaMEF2). Isolated neonatal rat cardiomyocytes (NRCM) were infected with AdMEF2A, AdcaMEF2 and control AdGFP for 48 h, fixed and stained for the sarcomeric proteins titin, at both the M-band (titin M8) and Z-disc (titin T12), a-actinin (Zdisk), and myomesin (M-band), ( Figure 1A and B). First, we determined the ratio of the length of the major and minor axis of cells, as a measure of cellular elongation. AdGFP infected cardiomyocytes had a ratio of 2.57 ± 0.16, while AdMEF2A and AdcaMEF2 infected cells displayed a two-and three-fold increase in major to minor axis ratios (5.20 ± 0.50 and 7.70 ± 0.77, respectively; P < 0.05) compared to AdGFP-infected cells ( Figure 1C) . Next, we analysed the MEF2-induced sarcomere phenotype. Non-infected and AdGFP infected NRCM displayed a regular pattern of sarcomere staining, with a regular spacing between the M-band and the Z-disc. In contrast, quantification of myofibrillar structure score showed a dramatic loss of sarcomeres in AdMEF2A and AdcaMEF2 infected NRCM ( Figure 1D) . Combined, these data demonstrate that MEF2 transcriptional activity in cultured cardiomyocytes promotes elongation of cardiomyocytes, accompanied by loss of sarcomere structure.
MEF2 activates cardiac genes involved in cardiomyocyte structure
To reveal the potential mechanisms underlying the structural cardiomyocyte changes induced by MEF2 transcriptional activity, we screened for MEF2 target genes. For this, we generated a cellular system to inducibly activate MEF2 in NkL-TAg cells, a previously described ventricular muscle cell line 13 (see Supplementary material online, Figure S1 and Figure 2A ). We obtained eight double-stable cell lines, which only expressed caMEF2 after Dox stimulation, as demonstrated by Western blotting using an anti-body against VP16 (see Supplementary material online, Figure S1B ) and by immunofluorescent staining (see Supplementary material online, Figure S1C ). To control for cell-based variations, we selected 2 TR-caMEF2 clones (TR1-194 and TR4-39) for further analysis. Both clones were transiently transfected with 3xMEF2 luc, mortalized 
with AdCre infection, 13 cultured for 72 h in serum free media to allow to adopt a ventricular muscle cell fate, and exposed to Dox for varying periods to establish at which time-course elevated MEF2 transcriptional activity was evident. In both clones, an approximate five-fold increase of MEF2 transcriptional activity was evident at 8 h, compared to TR1-194 and TR4-39 clones cultured in the absence of Dox ( Figure 2B ). After 24 h Dox exposure, both clones demonstrated an approximate 10-fold increase in MEF2 transcriptional activity ( Figure 2B ). Both TR1-194 and TR4-39 cell lines elongated after Cre-induced mortalization and Dox stimulation (see Supplementary material online, Figure S1D ). So, we established a novel system that allows inducible activation of MEF2 transcriptional activity in ventricular muscle cells by addition of Dox to the culture medium. Both inducible caMEF2 ventricular myocyte cell lines were used for a genome-wide microarray analysis to identify the earliest gene pattern regulated by MEF2. After cells were mortalized by AdCre infection, 13 cultured in serum free medium for 72 h and cultured for an additional 24 h in the absence or presence of Dox, we found 75 genes to be differentially expressed in both TR1-194 and TR4-39 cells with a fold change in expression > _2 (P < 0.01) after Dox stimulation (see Supplementary material online, Table S1 ). Gene ontology classifications revealed an over-representation of genes in several sub-classes, among which cellmatrix adhesion and cytoskeletal remodelling ( Figure 2C ). Another gene class differentially regulated by MEF2 included genes involved in energy metabolism and mitochondrial energy production ( Figure 2C ), which is in line with previous reports indicating a direct or indirect role for MEF2 to control cardiac energy production. 12, 14, 15 We picked 10 genes and verified differential expression by RT-PCR ( Figure 2D ) and QPCR analysis ( Figure 2E ). For example, transcripts for integrin alpha-7 (Itga7), nexilin (Nexn), connective tissue growth factor (Ctgf), regulatory myosin light chain 9 (Myl9), DMPK, sarcoglycan alpha (Sgca), and sarcoglycan beta (Sgcb) were upregulated upon caMEF2 expression in TR1-194 and TR4-39 clones ( Figure 2D and E). In contrast, transcripts for integrin beta 4 (Itgb4), glutathione S-transferase alpha 1 (Gsta1), and mucin 5 (Muc5b) were downregulated. Combined, these data demonstrate that MEF2 activates sub-sets of genes primarily involved in cardiomyocyte structure and energy metabolism.
DMPK is a MEF2 target gene required for loss of sarcomere structure
Of all genes found to be upregulated by MEF2 activation, DMPK was of specific interest. DMPK is a kinase related to the Rho family of kinases and has been implicated in disruption of sarcomere structure in earlier in vitro studies. 16, 17 Also, DMPK protein levels are increased in human failing hearts. 18 To verify that DMPK represents a direct transcriptional Figure 3A) . We performed ChIP analysis to determine whether MEF2 binds to this A/T rich motif ( Figure 3B) . Chromatin was immunoprecipitated from rat neonatal cardiomyocytes infected with either AdGFP or AdMEF2A, using anti-bodies directed against MEF2 and acetylated histone H3. No anti-body immunoprecipitates were used as negative control. PCR amplification of the immunoprecipitated material using primers flanking the MEF2 site, demonstrated MEF2 binding to the Dmpk promoter in cardiomyocytes infected with the MEF2A expressing adenovirus ( Figure 3B) . In order to assess the potential role of DMPK in MEF2-induced cardiomyocyte remodelling, we evaluated the effect of DMPK siRNAmediated knockdown during this remodelling process. As determined by Western blotting, we established significant knockdown of DMPK expression levels by transfecting cardiomyocytes with siRNAs directed against DMPK ( Figure 3C) . Infection with AdMEF2A and especially AdcaMEF2 enhanced DMPK protein levels in cardiomyocytes pretransfected with control siRNA. This increase in expression, however, was inhibited in cardiomyocytes pre-transfected with siRNA targeting DMPK ( Figure 3C) . Next, we investigated the effect of DMPK inhibition on MEF2-induced structural remodelling of cardiomyocytes. Pretransfection with control siRNA had no effect on cellular morphology. MEF2 activation induced elongation and loss of sarcomere structure in cardiomyocytes transfected with control siRNA ( Figure 3D) . Cardiomyocytes pre-transfected with DMPK siRNA, however, showed a clear attenuation of characteristic MEF2-induced sarcomeric degeneration ( Figure 3D) . Conclusively, DMPK is a direct cardiac MEF2 target gene and promotes loss of sarcomere structure. 3.4 DMPK E is increased in heart failure and is sufficient to induce loss of sarcomere structure
To assess a possible role for DMPK in loss of sarcomere structure in the intact heart, we analysed DMPK protein and mRNA levels in hearts from mice subjected to TAC or sham surgery (see Supplementary material online, Figure S2 ). Western blot analysis displayed a significant increase in DMPK protein levels only in failing mouse hearts [ejection fraction (EF) <35%] and not in hearts from mice with cardiac hypertrophy and preserved cardiac function ( Figure 4A and B) . DMPK RNA is subject to extensive alternative splicing, giving rise to six major (DMPK A-F) and several minor DMPK isoforms. 19 Alternative splicing events in the C-terminus (mainly resulting in in-or exclusion of exons 13 and 14) are likely to be the main determinants of DMPK functional variability, since they give rise to DMPK isoforms with long C-termini (DMPK A-D) that can anchor into membranes of mitochondria or the sarcoplasmic reticulum, or to smaller isoforms (DMPK E and F) with a cytosolic localization due to lack of the C-terminal extension. 20 So, we first determined the expression levels of different DMPK isoforms in failing mouse hearts and sham control hearts by RT-PCR using primers spanning exons 13 and 14 ( Figure 4C) . Interestingly, mainly the DMPK E isoform, resulting from skipping of both exon 13 and 14, was upregulated in failing hearts. Indeed, QPCR specifically for this isoform showed a significant increase in DMPK E mRNA in failing hearts ( Figure 4D) . Interestingly, RT-PCR and QPCR analysis in NRCM showed that it is particularly the DMPK E isoform that is upregulated upon MEF2 activation (see Supplementary material online, Figure S3A -C). Western blot analysis demonstrates that both the MEF2A and the caMEF2 construct increase DMPK protein levels (see Supplementary material online, Figure S3D ).
To further identify a role for DMPK E in sarcomere degeneration, we generated adenoviruses expressing either DMPK E (AdDMPK E) or a kinase dead mutant DMPK E [AdDMPK E (K100A); Figure 4E ] 20 and used these viruses, along with a GFP control virus, to infect isolated cardiomyocytes. Immunostaining for a-actinin and quantification of myofibrillar structure scores demonstrated a clear loss of sarcomere structure in NRCM 48 h after infection with AdDMPK E, but not with AdDMPK E (K100A) or AdGFP ( Figure 4F and G) . Overall, these data demonstrate that expression of DMPK E is increased in failing hearts and that overexpression of this specific isoform is sufficient to induce loss of sarcomeres in isolated cardiomyocytes. Furthermore, the DMPK E-induced effect on sarcomere structure requires DMPK E to be enzymatically active, indicating the involvement of one or more downstream phosphorylation events.
DMPK E inhibits SRF transcriptional activity
Loss of sarcomeres can be induced by both an increase in sarcomere protein degradation and a decrease in sarcomere generation. To test this, we performed QPCR analysis for several sarcomeric genes, including a-actinin (Actn2), titin (Ttn), synaptopodin 2-like (Chapb), skeletal alpha actin (Acta1), and myosin light chain 2 (Myl2) on RNA isolated from NRCM infected with AdGFP, AdDMPK E, AdDMPK E (K100A), and AdcaMEF2 ( Figure 5A) . Strikingly, the expression of all sarcomeric genes tested was dramatically reduced in NRCM infected with AdDMPK E compared to cells infected with AdGFP or AdDMPK E (K100A). A smaller, but still significant, decrease in Actn2, Ttn, Acta1, and Myl2 mRNA was also observed in NRCM infected with MEF2 virus, which is in line with DMPK being the MEF2 target involved in sarcomere loss ( Figure 3D) . The expression level of cardiac NK2 homeobox 5 (Nkx2.5) was similar in all conditions ( Figure 5A) , assuring an equal number of cardiomyocytes after infection with the different viruses. So, DMPK E-induced loss of sarcomeres is caused by a decrease in transcription of sarcomeric genes. Interestingly, among the few known phosphorylation targets of DMPK is SRF, a transcription factor controlling cardiac sarcomere gene expression. 21 To check whether DMPK E inhibits SRF transcriptional activity in our cardiomyocytes, we transfected NRCM with the SM22 luc reporter for SRF activity together with or without the SRF cofactor myocardin (Myocd). 22 At baseline, luciferase signal in AdDMPK E infected NRCM was significantly lower than in AdGFP or AdDMPK E (K100A) infected cells. Furthermore, co-transfection with Myocd resulted in a significant increase in luciferase signal, indicating enhanced SRF activity, in cells infected with AdGFP and AdDMPK E (K100A), but not in cells infected with AdDMPK E ( Figure 5B ). These data demonstrate that DMPK E inhibits SRF transcriptional activity. DMPK is known to phosphorylate threonine 159 and possibly serine 162 in the MADS box, the DNA binding domain of SRF. 21 These phosphorylation events have been described to weaken the binding of SRF to the promoter regions of sarcomeric genes, thereby decreasing their expression levels. 23 ,24 Therefore, we explored the potential effects of DMPK E on cellular localization of SRF by immunostainings ( Figure 5C and D). NRCM infected with AdGFP or AdDMPK E (K100A) displayed an expected nuclear localization of SRF. In contrast, AdDMPK E infected NRCM showed a significant increase in translocation of SRF from the nucleus ( Figure 5C and D) . Next, we compared the effect of the full-length DMPK A isoform and the cytosolic DMPK E isoform on both sarcomere disruption and SRF translocation in NRCM (see Supplementary material online, Figure S4 ). NRCM transduced with DMPK E showed a much larger sarcomere disorganization and more SRF translocation than NRCM transduced with DMPK A, indicating that it is the cytosolic variant of DMPK that induces SRF translocation and thereby sarcomere disruption. Combined, DMPK E decreases transcription of sarcomeric genes, due to an SRF nucleo-cytoplasmic translocation event and concomitant inhibition of SRF transcriptional activity.
DMPK E-induced loss of sarcomere structure requires phosphorylation of SRF
DMPK is known to phosphorylate SRF at threonine 159 and serine 162. 21 To investigate whether phosphorylation of SRF is the main mechanistic driver for DMPK E-induced sarcomere degeneration, we generated lentiviruses expressing either wildtype SRF (SRF-WT), a nonphosphorylatable mutant SRF in which the serine and threonine sites have been mutated to alanine (SRF-TASA), and a phosphomimic mutant in which these sites have been mutated to aspartic acid (SRF-TDSD).
We then co-infected NRCM with these viruses and with either AdGFP or AdDMPK E, and assessed the amount of nuclear SRF ( Figure 6A and B). Quantification of the percentage of nuclear SRF showed that the phosphomimic TDSD SRF mutant translocates out of the nucleus independent of DMPK E. Furthermore, the SRF-TASA mutant remains located in the nucleus even in the presence of DMPK E. Since the unphosphorylatable TASA SRF mutant remains located in the nucleus, we investigated the effect of SRF-TASA overexpression on AdDMPK E-induced loss of sarcomeres ( Figure 6C) . Quantification of the myofibrillar structure showed that NRCM infected with lenti-SRF-TASA were protected from DMPK E-induced sarcomere disruption ( Figure 6D) . Combined, these results demonstrate that DMPK E-induced loss of sarcomeres requires phosphorylation of SRF.
DMPK E activity induces loss of cardiac sarcomere structure and cardiomyopathy in mice
Our in vitro findings indicate that DMPK is required for MEF2-induced sarcomere loss and that DMPK E is sufficient to induce loss of sarcomere structure. To define whether DMPK E is also sufficient to induce structural remodelling of the heart, we generated mice expressing either DMPK E or DMPK E (K100A) under control of the cardiac specific alpha myosin heavy chain promoter. For both constructs we obtained two independent transgenic lines, designated DMPK E lines 1 and 2 and DMPK E (K100A) lines 1 and 2, with matched levels of overexpression as determined by Western blot analysis ( Figure 7A) . QPCR analysis indicates that DMPK E mRNA levels in DMPK E (K100A) hearts are higher than in the DMPK E mouse lines ( Figure 7B) . DMPK E mRNA levels in DMPK E line 2 hearts are lower compared to DMPK E line 1 hearts ( Figure 7B) . So, hearts of control DMPK E (K100A) mice express equal or slightly higher amounts of DMPK E protein compared to DMPK E mice. However, DMPK E (K100A) mice lack DMPK kinase activity, as depicted by the absence of DMPK autophosphorylation (no higher DMPK protein product on Western blot; Figure 7A) .
Strikingly, survival rate was significantly reduced in both DMPK E lines, with mortality of 70% and 20% in 7-month-old DMPK E line 1 and DMPK E line 2 mice, respectively, compared to no mortality in wildtype (WT) or both DMPK E (K100A) mouse lines ( Figure 7C) . Hearts from 8-month-old DMPK E (K100A) mice displayed no structural abnormalities compared to age matched WT hearts ( Figure 7D) . Hearts from DMPK E transgenic mice, however, showed clear signs of cardiomyopathy, with dilation of both ventricles and occasional enlargement of atria, at an age of 5 and 8 months for lines 1 and 2, respectively ( Figure 7D) . Next, we performed echocardiographic analysis of WT, DMPK E and DMPK E (K100A) mice to assess cardiac dimensions and function over time. Although we did not find any differences in wall thickness or ventricular diameter within 6 months of age, DMPK E transgenic mice displayed a clear loss of cardiac function compared to WT and DMPK E (K100A) control mice (see Supplementary material online, Figure S5A) . To assess the amount of fibrosis, we performed Sirius Red stainings, which showed a significant increase in fibrotic cardiac tissue in DMPK E mice (see Supplementary material online, Figure S5B ). To investigate whether the DMPK E phenotype could be due to increased cardiomyocyte death, we assessed the extent of cardiomyocyte apoptosis by TUNEL staining (see Supplementary material online, Figure S6 ). These data demonstrated that there is no increase in cardiomyocyte apoptosis in DMPK E transgenic mice. The cardiomyopathic phenotype was further illustrated by a significant increase in heart weight-to-tibia length and lung weight-to-tibia length ratios in both 4-5 month-old DMPK E line 1 and 8-10 month-old DMPK E line 2 transgenic mice, compared to 8-10 month-old WT mice ( Figure 7E and F) . This increase in heart and lung weights was not observed in 8-10 month-old DMPK E (K100A) mice ( Figure 7E and F) . So, an increase in DMPK E kinase activity in post-natal hearts results in cardiomyopathy and death.
To obtain more mechanistic insight in the DMPK E induced cardiomyopathy, we sacrificed mice at 10 weeks of age and performed electron microscopy on cardiac tissue ( Figure 7G and H and see Supplementary material online, Figure S5C ). Quantification of sarcomere structure score indicated that sarcomere structure is severely disrupted in DMPK E transgenic mice ( Figure 7H) . Staining of cardiac sections for a-actinin further verified a loss of sarcomere structure in DMPK E mice compared to both WT and DMPK E (K100A) mice ( Figure 7I) .
Furthermore, immunostaining for SRF revealed a significant decrease in cardiomyocytes with an SRF positive nucleus in DMPK E mice compared to WT and DMPK E (K100A) mice ( Figure 7I and J) . In line, QPCR for SRF-regulated sarcomeric genes revealed a significant decrease of Ttn, Actn2, and Myl2 expression in DMPK E mice, compared to both WT and DMPK E (K100A) control mice ( Figure 7K) . In contrast to our observations in NRCM ( Figure 5A ), Acta1 mRNA levels were significantly higher in DMPK E hearts ( Figure 7K) , which could be due to the reactivation of the fetal gene program during cardiac stress. Overall, an increase in DMPK E kinase activity in the heart results in cardiomyopathy. This cardiomyopathy is preceded by a loss of sarcomere structure and inhibition of SRF transcriptional activity.
Discussion
Ultrastructural changes in cardiomyocytes are characteristic features of heart failure development and disruption of sarcomeres is found to be an early predictor of prognosis in dilated cardiomyopathy patients. 25 Previous work has demonstrated the contribution of MEF2 to structural remodelling of cardiomyocytes in heart failure progression, 4, 5, 11 but the underlying mechanism and responsible MEF2 transcriptional targets are unknown. In present study, we confirmed the importance of MEF2 in adverse cardiomyocyte remodelling, since MEF2 activation induced elongation of cardiomyocytes and loss of sarcomere components at both the M-band and Z-disc. Concordantly, the classification profile of MEF2 target genes we identified revealed an intimate involvement of MEF2 in regulation of cellular structure. We identified DMPK as direct transcriptional target of MEF2 with a crucial role in disruption of sarcomere structure (see Supplementary material online, Figure S7 ). DMPK did not seem to affect cardiomyocyte length, indicating that the MEF2-induced cardiomyocyte elongation involves other MEF2 transcriptional targets. DMPK protein levels are found to be increased in human failing hearts, 18 but DMPK is mainly known from its implication in myotonic dystrophy 1 (DM1). DM1 is an inherited multi-systemic neuromuscular disorder and symptoms include progressive muscle weakness and wasting, cataracts, gastro-intestinal problems, and cardiac abnormalities. 26 DM1
has been associated with expansion of untranslated CTG repeats in the 3'-untranslated region of DMPK, which causes accumulation of DMPK mRNA transcripts in the nucleus, resulting in RNA toxicity and trans effects altering expression and alternative splicing of numerous other genes. 27, 28 It is unclear, however, whether these trans RNA processing defects are solely responsible for the DM1 cardiac pathology, since altered DMPK levels are by itself sufficient to induce cardiac defects similar to those observed in DM1 patients. 29, 30 Nevertheless, most studies on DM1 focus on the pathological effects associated with the untranslated CTG expansion, leaving a functional role for DMPK largely unexplored. Findings in several other studies underline the potential role for DMPK in cardiomyocyte remodelling. DMPK is related to the Rho family of protein kinases, which are associated with actin cytoskeletal remodelling. 31 DMPK is also known to interact with Rac-1, and both DMPK and Rac-1 are able to phosphorylate and inhibit myosin phosphatase. 32 17 Their results suggest that the effects of DMPK E on sarcomere structure mainly involve a disturbance in sarcomere formation instead of active breakdown of sarcomere components, which is in agreement with our findings that DMPK E inhibits sarcomeric gene expression. A recent report by Carell et al. 35 suggests that targeting all DMPK isoforms in mice is not sufficient to prevent loss of cardiac function after induction of pressure overload. In their study, however, they only investigated the effect of DMPK inhibition during early cardiac remodelling and not in end-stage heart failure, when DMPK E is upregulated and a disturbance in sarcomere formation is expected.
The absence of any morphological or functional changes after overexpression of the kinase dead DMPK mutant in both our in vitro and in vivo experiments indicates the requirement of DMPK enzymatic activity and one or more downstream phosphorylation targets in the cellular remodelling process. Besides myosin phosphatase, DMPK is known to phosphorylate a small set of other targets, including phospholamban, 36 phospholemman, 37 CUG-binding protein, 38 and SRF. 21 Like MEF2, SRF is a MADS box containing transcription factor essential for cardiac differentiation. SRF binds to a DNA consensus element known as CArG box, which is primarily found in promoters of genes involved in cell growth, cell movement, and contractility. 24 The importance of SRF in the heart is illustrated by several studies in mouse models, which demonstrate that SRF loss of function results in dilated cardiomyopathy and death associated with decreased levels of sarcomeric proteins. QPCR analysis of SRF-regulated sarcomeric genes in WT (Ttn: n = 4, Actn2: n = 4, Myl2: n = 4, Acta1: n = 5), DMPK E (Ttn: n = 5, Actn2: n = 4, Myl2: n = 6, Acta1: n = 4) and DMPK E (K100A) (Ttn: n = 3, Actn2: n = 3, Myl2: n = 4, Acta1: n = 4) transgenic mice. *P < 0.05, **P < 0.01, ***P < 0.001 vs. WT; # P < 0.05, ## P < 0.01, ### P < 0.001 vs. DMPK E, one way ANOVA followed by Tukey's post-test.
